Consistently, we found that CYT387 treatment resulted in the downregulated expression of both IKBKE and RRM2, and CYT387 effectively inhibited renal cancer cell proliferation and arrested the cell cycle at the G2/M checkpoint. Here, IKBKE is linked to renal carcinoma.